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Abstract
Background—A variety of NADPH oxidase (Nox) isoforms including Noxs 1, 2, 4 and 5 
catalyze the formation of reactive oxygen species (ROS) in the vascular wall. The Nox2 isoform 
complex has arguably received the greatest attention in the progression of atherogenesis in animal 
models. Thus, in the current study we postulated that specific Nox2 oxidase inhibition could 
reverse or attenuate atherosclerosis in mice fed a high-fat diet.
Methods—We evaluated the effect of isoform-selective Nox2 assembly inhibitor on the 
progression and vascularization of atheromatous plaques. Apolipoprotein E-deficient mice (ApoE
−/−) were fed a high fat diet for two months and treated over 15 days with Nox2ds-tat or control 
sequence (scrambled); 10 mg/ kg/day, i.p. Mice were sacrificed and superoxide production in 
arterial tissue was detected by cytochrome C reduction assay and dihydroethidium staining. Plaque 
development was evaluated and the angiogenic markers VEGF, HIF1-α and visfatin were 
quantified by real time qRT-PCR. MMP-9 protein release and gelatinolytic activity was 
determined as a marker for vascularization.
Results—Nox2ds-tat inhibited Nox-derived superoxide determined by cytochrome C in carotid 
arteries (  protein; P < 0.01) and caused a significant 
regression in atherosclerotic plaques in aorta (66 ± 6 μm2 vs 37 ± 1 μm2; scrmb vs. Nox2ds-tat; P 
< 0.001). Increased VEGF, HIF-1α, MMP-9 and visfatin expression in arterial tissue in response 
to high-fat diet were significantly attenuated by Nox2ds-tat which in turn impaired both MMP-9 
protein expression and activity.
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Conclusion—Given these results, it is quite evident that selective Nox inhibitors can reverse 
vascular pathology arising with atherosclerosis.
Keywords
Vascular Nox; Vulnerable plaque; Oxidative stress
1. Introduction
Chronic vascular inflammation, an important feature of atherosclerosis, propagates 
vasculopathy in large conduit vessels exhibiting atherosclerotic plaque formation [1]. This 
process is accelerated by the adhesion, migration and accumulation of lymphocytes and 
monocytes into the vessel wall [2]. In atherosclerosis, inflammatory leukocyte recruitment 
into the vessel wall is facilitated by the increasingly dense, wide and arborized vasa 
vasorum, whose development seems to originate via the recruitment of vascular progenitor 
cells in the vascular adventitia [3,4]. The concept that neovascularization from the vessel 
wall may play a key role in the pathophysiology of atherosclerosis was theorized over a 
century ago [5]. Experimental evidence associating angiogenesis in atherosclerotic plaque 
with a more unstable and progressive atherosclerotic disease has been highlighted by the fact 
that neointimal microvessel may increase delivery of cellular and soluble lesion components 
to the vessel wall [6]. The vasa vasorum constitutes a network of microvasculature that 
originates primarily in the adventitial layer of large arteries. The adventitia is where 
formation and regression of microvessels that penetrate and nourish the media and intima are 
controlled [7]. Considerable interest has been focused on the study of the formation of these 
microvessels and its role in atherosclerotic plaque. Recent evidence suggests a key role for 
reactive oxygen species (ROS) in these processes [8,9]. In most blood vessels the main 
source of ROS appears to be the NADPH oxidase (Nox) family of proteins (Noxs 1, 2, 4 and 
5) variably expressed by vascular endothelial cells, smooth muscle cells and adventitial 
fibroblasts [10]. ROS are known players involved in the initiation and progression of cell 
proliferation and migration. Changes in cellular biochemistry, such as levels of inflammatory 
marker molecules and redox imbalance in reducing systems, have fundamental importance 
in the atherogenic process [11,12]. Antioxidants, like polyphenols [13], and agents such as 
apocynin [14] (albeit non-specific) that disrupt ROS production derived from NADPH 
oxidase, reverse vascular remodeling, improve endothelial function and reduce 
inflammation. Coronary artery disease (CAD) is associated with increased NADPH oxidase 
subunit expression, mainly p22phox and Nox2, related in part to higher monocyte/
macrophage infiltration [8]. Indeed, a study by Barry-Lane et al. supports the latter, that is, 
deletion of essential Nox2 oxidase subunit p47phox prevents the progression of plaque 
formation in ApoE−/− mice [15]. In an attempt to gain maximal selectivity for some Nox 
isoforms, development of peptidic inhibitors targeted at disrupting assembly of Nox 
complexes has garnered significant interest [16]. Nox2ds-tat, a cell-permeant inhibitor 
targeting the assembly of Nox2, is a peptide that binds to the p47phox subunit and prevents 
its key interaction with the core membrane-integrated cytochrome b558 protein Nox2 [17]. 
Nox2ds-tat also blocked angiotensin II (AngII)-induced superoxide production in human 
resistance artery smooth muscle cells [18]. Many other studies have proven its efficacy to 
inhibit Nox2 in disrupted and intact cells as well as whole tissue and animal models [18–21]. 
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Thus, we hypothesized that specific Nox2 inactivation would arrest atheroma plaque 
progression and instability and thus reverse the dangers of an unstable plaque. For that 
purpose, this study was designed to evaluate the ability of Nox2ds-tat peptide to disrupt the 
progression and vascularization of atheroma plaque in apolipo-protein E-deficient (ApoE−/
−) mice and address the underlying mechanism, focusing on the association between 
inflammation, oxidative stress and accelerated atherosclerosis.
2. Materials and methods
2.1. Ethical approval
All animals were cared for in accordance with the Guiding Principles in the Care and Use of 
Animals of the US National Institutes of Health (NIH). All procedures were approved by the 
Animal Research Committee of the National University of Cuyo (protocol approval #8/2012 
CICUAL, School of Medical Science, Mendoza, Argentina).
2.2. Animal model
Male C57/BL6J ApoE−/− mice 8 weeks of age (20–22 g; The Jackson Laboratories, Bar 
Harbor, ME) were used for this study. Mice had unrestricted access to water and standard 
chow (GEPSA, Argentina) and were maintained on a 12 h light/dark cycle under pathogen-
free conditions in the Genetically Modified Animal Lab, School of Medical Science, 
National University of Cuyo. Mice were randomly divided into four groups (n = 4–6 mice 
each) and fed a control diet (Control), high fat diet (HFD) (15.8% fat, 1.25% cholesterol; 
Gepsa, Argentina) for eight weeks, HFD + Nox2 inhibitor peptide (a chimeric 18-amino acid 
peptide ([H]-R-K-K-R-R-Q-R-R-R-C-S-T-R-I-R-R-Q-L- [NH2]) [18] that has been shown 
to inhibit NADPH oxidase activity in vivo and in vitro) and HFD plus control sequence 
(scrambled). Peptides (10 mg/kg/day) were injected i.p. over a 2 week period.
2.3. Biochemical determinations
After overnight fasting, blood samples for glucose, triglycerides, and cholesterol 
determinations (GT Lab, Buenos Aires, Argentina) were drawn from all animals, collected 
from cardiac puncture under anesthesia at the end of the experimental period.
2.4. Determination of tissue Nox-derived superoxide and vascular oxidant level
Tissue  was calculated from the initial linear rate of SOD-inhibitable cytochrome C 
reduction quantified at 550 nm using the extinction coefficient of 21.1 mM−1 cm−1 as 
previously described [22]. Briely, isolated carotid arteries were homogenized in buffer 
containing 8 mM potassium, sodium phosphate buffer, pH 7.0, 131 mM NaCl, 340 mM 
sucrose, 5 mM MgCl2, 1 mM EGTA, and protease inhibitors (Roche); and centrifuged at 
10,000 rpm for 15 min at 4 °C to remove unbroken cells, nuclei and debris. The assay of the 
supernatant was carried out using acetylated cytochrome C (0.2 mM, Sigma–Aldrich), in 
buffer containing catalase (300 U/ml) to prevent re-oxidation of reduced cytochrome C by 
H2O2. An identical set of samples was incubated in the presence of SOD (150 U/ml) for 
subtraction of the SOD-inhibitable signal. After 5 min baseline measurement, NADPH (180 
μM) was added and  production was measured at 550 nm using a UV–visible 
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spectrophotometer (Mutiskan FC, Thermo Fisher). Superoxide production is expressed as 
nmoles  protein using the extinction coefficient.
In situ vascular superoxide anion was approximated using dihydroethidium (DHE) as 
previously described [23]. Briefly, freshly isolated vascular segments (aortas and carotid 
arteries) from each treatment were embedded in tissue freezing medium and 6 μM 
cryosections were mounted on cover slips. DHE dissolved in PBS to final concentration of 5 
μmol/l was added and incubated at 37 °C in dark for 30 min. Images were captured with a 
fluorescent microscope and three to six images were acquired from three sections per vessel 
ring for each experimental condition (n = 4 in each experimental group). Images were 
analyzed with ImageJ 1.37v software (NIH) and changes in total fluorescence intensity were 
calculated relative to control.
2.5. Quantification of atherosclerotic plaques
Plaque area was quantified by Oil-red-O staining of lipid deposits. Vessels were incubated 
for 45 min with Oil red O (0.5% in 60% isopropyl alcohol). Excess stain was removed with 
60% isopropyl alcohol. Quantification of atherosclerosis was performed in the aortic arch 
region up to the descending abdominal aorta by computer-assisted image analysis. 
Subsequently images of en face preparations of the whole mounted aorta were taken and the 
percentage of plaques in relation to the entire aortic surface calculated as plaque score in 
percent of total area using ImageJ 1.37v software (NIH).
2.6. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis
Total RNA was isolated with the Trizol (Invitrogen) method from carotid tissue pools (6 per 
group), 1 μg of total RNA was reverse-transcribed, using random primer hexamers 
(Biodynamics, SRL) and M-MLV reverse transcriptase (Promega), according to the 
manufacturer's instructions. Real-time PCR was performed with the cDNA samples, primers 
(Invitrogen) and EVA Green (GenBiTech, Argentina) by using a Rotor-Gene 6000 Series 
Software version 1.7 (Corbett). All samples were amplified in triplicate. The relative 
changes in the amount of transcripts in each sample were determined by normalizing with 
the actin RNA levels.
2.7. Western blotting
Western blot analysis of MMP-9 expression was performed on carotid tissue homogenates 
from 4 animals per group using rabbit-anti MMP-9 antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA), and HRP-conjugated secondary antibodies (1:10,000 Jackson laboratory, 
US). Proteins were visualized by performing luminol-enhanced chemiluminescence. 
Loading of equal amounts of proteins was confirmed by re-probing the membrane with an 
antibody against β-actin (1:100; Santa Cruz Biotechnology, Santa Cruz, CA). Protein 
expression was quantified using ImageJ 1.37v software (NIH).
2.8. MMP-9 Activity by gelatin zymography
Soluble protein extracts were obtained by pulverizing pooled carotid arteries (n = 4) from 
each treatment in liquid nitrogen, placed in lysis buffer without protease inhibitors and 
centrifuged at 21,000 g for 20 min at 4 °C. Protein quantification was performed by the 
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Bradford method and samples were diluted with a buffer containing 12.5% 0.5M Tris HCl 
pH 6.8, 10% glycerol, 4% SDS, and 0.05% bromophenol blue, without mercaptoethanol to 
avoid denaturation and to maintain biological activity. Gelatin zymography is mainly used 
for the detection of the gelatinases, MMP-2 and MMP-9, respectively. The assay is highly 
sensitive because levels of 10 pg of MMP-9 can be detected [24]. It was performed together 
with molecular weight markers using 8% SDS-polyacrylamide separating gels with 1% of 
gelatin (a suitable substrate for MMP-2 and MMP-9), 30% bis-acrylamide, 1.5M tris-HCL 
pH 8.8, 10% ammonium persulfate, 0.04% TEMED, 10% SDS. Electrophoresis was carried 
at 4 °C using a constant current of 20 mA during 3 h. Gels were washed twice in 2% Triton-
x 100 for 15 min and three times with distilled water, incubated in buffer (Tris 0.25 M, 
CaCl2 25 mM, NaCl 1M, pH 7.6) for 48 h at 37 °C, stained with 0.1% Coomassie brilliant 
blue, 40% methanol and 10% acetic acid, for 1 h, under gentle shaking, and de-stained for 
20 min with 25% ethanol/8% acetic acid solution. Gels were photographed and the enzyme 
gelatinolytic activity was determined by densitometry and analyzed with ImageJ Software. 
Collagenase was used as a positive control.
2.9. Data analyses
All values are expressed as means ± S.E.M. Comparisons across the four groups were 
analyzed using a one-way ANOVA, followed by a Bonferroni's post-hoc test to determine 
significant differences between two groups (Prism v4, GraphPad). Differences between 
groups with a P-value <0.05 was considered statistically significant.
3. Results
3.1. Biochemical parameters
Metabolic characteristics for each experimental group are outlined in Table 1. Glycemia and 
dyslipidemia were largely unaffected by treatment with Nox2 inhibitor.
3.2. Vascular superoxide anion measurement and NADPH oxidase gene expression
Nox-derived superoxide anion ( ) determined by cytochrome C in homogenized carotid 
tissue from ApoE−/− mice on a high fat diet, significantly increased compared to control 
diet, and chronic treatment with Nox2ds-tat, 10 mg/kg*d, significantly reduced this effect 
(Fig. 1A). We evaluated in carotid arteries the mRNA levels of core subunits Nox1, Nox2, 
and Nox4 and observed that Nox2ds-tat treatment induce a moderate decrease in the 
expression of Nox1 which did not reach significance, and did not cause any change in the 
expression of the other core vascular isoforms, i.e. Nox2 and Nox4 (Fig. 1B). However, 
Nox2ds-tat significantly inhibited mRNA expression of both p47phox and p22phox, compared 
with scrambled control. Next, we confirmed an increased vascular superoxide anion level in 
situ in aortic sections from HFD-treated ApoE−/− mice injected with control peptide, using 
redox-sensitive dihydroethidium (DHE). Fig. 2 shows the qualitative analysis of DHE 
staining. Findings in aortic tissue from HFD-ApoE−/− mice treated with Nox2ds-tat are 
consistent with a decreased oxyethidium signal compared with aortas from HFD-ApoE−/− 
mice treated with scrambled peptide. Similar results were found in carotid artery 
cryosections (data not shown).
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3.3. Assessment of atherosclerotic lesions in the aorta
Eight weeks of high fat diet caused an increase in atherosclerotic plaques within the aorta as 
assessed by Oil Red O staining (Fig. 3). Two weeks subsequent treatment with Nox2ds-tat 
significantly reduced lesion area in aortas from ApoE−/− mice in comparison with aortas 
scrambled-treated ApoE−/− mice. Similar results were found in carotid arteries cryosections 
(data not shown).
3.4. Effect of Nox2 inhibition on pro-angiogenic mediators
Shared angiogenic and oxidative mechanisms underlie the pathophysiology of 
atherosclerosis. Thus, we sought to investigate the mRNA expression of pro-angiogenic 
factors such as vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α 
(HIF-1α) in ApoE−/− mice treated with Nox2ds-tat. We found a significant increase in both 
VEGF and HIF-1α expression in carotid arteries from high fat fed-ApoE−/− mice (Table 2), 
and treatment with Nox2ds-tat significantly reduced the expression of both angiogenic 
mediators.
Visfatin, an adipokine that possesses angiogenic properties, can induce VEGF and VEGF 
receptor 2 (VEGFR2) expression by activating both the PI3K/Akt and the ERK1/2 signaling 
cascades [25], and enhanced VEGF signaling results in increased expression of 
metalloproteinases (MMP) which promote many of the adverse structural changes associated 
with plaque vulnerability. Based on these findings, we decided to quantify visfatin and 
MMP-9 gene expression in our model. We found a significant reduction in mRNA 
expression of visfatin and MMP-9 expression in carotid artery from HFD treated-ApoE−/− 
mice treated with Nox2ds-tat (Table 2) suggesting that Nox2 inhibition reverses 
neovascularization induced by a high fat diet.
3.5. Effect of Nox2 inhibition on the stability of the atheroma
We set out to investigate the effect of Nox2 inhibition on plaque stability by analyzing 
MMP-9 expression, by Western blot and determining MMP-9 activity by gelatin 
zymography. Nox2ds-tat significantly inhibited HFD-simulated MMP-9 protein expression 
(Fig. 4A). MMP-9 activity in homogenates of carotid arteries was enhanced by a fat-rich diet 
and this effect was inhibited by Nox2ds-tat (Fig. 4B) suggesting that Nox2 inhibition could 
help to maintain the stability of atherosclerotic plaques by decreasing the factors involved in 
the breakdown of the atheromatous plaque.
4. Discussion
Increased cellular oxidative stress has been proposed to contribute to plaque progression 
leading to plaque instability. Previous studies in human indicate that Nox2 hereditary 
deficiency is associated with reduced atherosclerotic burden [26] and in this “human 
knockout” model of NADPH oxidase, arterial dilatation was also enhanced [27], thus 
providing evidence that this ROS-generating pathway is implicated in modulating arterial 
tone and in human atherosclerosis. Interestingly patients with p47phox hereditary deficiency 
had intermediate flow-mediated dilation and oxidative stress [28]. Changes in the NADPH 
oxidase system may contribute to smooth muscle cell phenotypes associated with unstable 
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atherosclerotic plaques [29], and new therapeutic strategies for cardiovascular disease based 
on prevention of ROS production, include the development of less toxic and more selective 
NADPH oxidase inhibitors, allowing clarification of the role of each NADPH oxidase 
isoform and its potential use in clinical practice [16]. In this study we sought to investigate 
whether specific inhibition of NADPH oxidase decreases the progression of atheromatous 
plaques and reduces the pro-angiogenic mediators that lead to increase plaque risk for 
rupture. Nox2ds-tat is an efficacious inhibitor of Nox2-NADPH oxidase and although as a 
peptide in its native state it has limited oral bioavailability, parenteral delivery methods are 
effective at reducing vascular pathologies associated with increased ROS production [30]. 
Furthermore, Nox2ds-tat is an isoform-specific inhibitor as evidenced by its lack of 
inhibition of ROS production in either the COS-Nox1 (canonical or hybrid), the COS-Nox4 
oxidase systems or xanthine oxidase [31]. In our study, we demonstrated that the 
administration of Nox2ds-tat to ApoE−/− mice fed a Western type diet resulted in a 
significantly reduced in Nox-derived superoxide in the vascular wall, with associated 
downregulation of the expression of membrane-bound subunit p22phox and the cytosolic 
p47phox, a key interaction in the assembly of the active NADPH oxidase complex (the 
p47phox bis-SH3 domain and a proline-rich region present on the carboxy terminal of 
p22phox [32]). Although transcriptional regulation of Nox subunits by oxidants has not been 
an extensive focus of investigation, these data could suggest a feed forward transcriptional 
activation of Nox subunits by reactive oxygen species. Most importantly, the decrease in 
oxidative stress in the arterial wall led to a reduction of atheroma development in aorta and 
carotid arteries from high-fat fed ApoE−/− mice, suggesting an atheroprotective effect of 
this peptide. Sibley et al. reported reduced carotid but not coronary artery atherosclerosis in 
patients with chronic granulomatous disease (CGD) who have an immunodeficiency of the 
phagocyte NADPH oxidase and a concomitant reduction in reactive oxygen species [33]. 
CGD raises questions about the role of NADPH oxidase in the pathogenesis of clinically 
significant atherosclerosis. We focused on the effect of Nox2 inhibition on the progression 
(and regression) and vascularization of atheromatous plaques. The enlargement of the 
atheroma provokes intra-plaque hypoxia that triggers inflammatory cell infiltration, thus 
promoting local neo-vascularization. Interestingly, although intimal thickening is believed to 
be an early surrogate marker for atherosclerosis, pathological neovascularization is 
implicated in both early and late stages of the disease [34]. Angiogenesis is increased in 
lipid-rich plaque and neovascularization has been linked to the progression and vulnerability 
of atherosclerotic lesions [35]. HIF-1α is a key transcriptional regulator responding to 
hypoxia and activating genes, which promote angiogenesis, among them VEGF. Based on 
those data, we explored gene expression of different pro-angiogenic factors in carotid 
arteries homogenates. We found that high fat diet elevates the expression of VEGF and 
HIF-1α and that Nox2ds-tat treatment reduces this effect significantly. This is in accordance 
with previous report that showed that Nox2-containing NADPH oxidase deficiency (Nox2-
deficient mice) protects against age-dependent impairment of neovascularization [36]. We 
also detected the expression of others genes associated with VEGF signaling, such as 
visfatin and metalloproteinases (MMP)-9. Both proteins displayed parallel overexpression in 
inflammatory cells, especially in the neovascularized plaque lesions. An intense expression 
of VEGF and MMP-9 in carotid plaques is related to plaque instability, high degree of 
stenosis and presence of symptomatic carotid occlusive disease [37]. On the other hand, 
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Adya et al. demonstrate that the adipokine visfatin can induce endothelial cell (EC) 
proliferation and angiogenesis by stimulating the VEGF system. In particular, they showed 
that visfatin induces VEGF and VEGFR2 and enhanced VEGF signaling results in increased 
expression of MMP-2 and MMP-9 [25]. Visfatin plays important roles in angiogenesis, and 
was also shown to induce the expression of HIF1α and MMP production and activity 
[38,39]. This adipokine should be regarded as an inflammatory mediator, localized to foam 
cell macrophages within unstable atherosclerotic lesions, that potentially plays a role in 
plaque destabilization [40]. Interestingly, we found in our study that Nox2ds-tat 
administration significantly reduced the expression of visfatin and MMP-9 and specifically 
inhibited the gelatinolytic activity of MMP-9 which would be expected to result in decreased 
plaque vulnerability.
Inflammation and oxidative stress are closely associated with the activation of MMPs, which 
induces extracellular matrix degradation, resulting in the development and progression of 
atherosclerosis and plaque instability. Thus, MMPs are pivotal downstream components in 
the pathogenesis of atherosclerosis. Macrophages, which are abundant in ruptured 
atherosclerotic plaques, express multiple MMPs, weakening the plaque and making it 
ruptures prone [41]. Among MMPs, MMP-9 (92-kDa gelatinase B), which is a prevalent 
isozyme expressed by activated macrophages and foam cells, is found in human coronary 
atherosclerotic lesions [42]. Therefore, attenuation of macrophage infiltration may largely 
contribute to the decreased MMP activity.
Our findings are ostensibly in contrast with a recent experimental study in Nox2-deficient 
mice in which MMP-9 activity in the adventitia, but not media, was upregulated in 
aggravated abdominal aortic aneurysm (AAA) lesions, suggesting that a deficiency in Nox2 
markedly perturbs proinflammatory cascades in macrophages present in AAA [43]. Thus, it 
is important to carefully monitor inflammatory phenotype when Nox2 intervention is 
conducted and this issue will also need to be investigated in humans.
In summary, we demonstrated for the first time to our knowledge that Nox2ds-tat, the 
inhibitor of Nox2 oxidase, exerts a significant protective effect against the progression of 
atherosclerosis by mechanisms including inhibition of oxidative stress and angiogenic 
mediator downregulation, resulting in regression of atheromatous plaques. This salutary 
effect appears to also decrease plaque neovascularization linked to the vulnerability of 
atherosclerotic lesions.
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Abbreviation
ApoE−/− ApoE-deficient mice
NADPH nicotinamide adenine dinucleotide phosphate
ROS reactive oxygen species
VEGF vascular endothelial growth factor
HIF hypoxia inducible factor
MMP-9 metalloproteinase 9
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Fig. 1. 
Effect of Nox2ds-tat peptide on Nox-derived superoxide ( ) and NADPH oxidase 
components expression: (A) Nox-derived superoxide was measured by cytochrome C 
reduction assay in homogenates of carotid arteries from ApoE−/− mice fed a control diet or 
high fat diet (HFD) for 8 weeks and treated with Nox2ds peptide or scrambled peptide the 
final 2 weeks. Values are mean ± SEM (n = 4), **P < 0.001 vs control chow; §P < 0.01 vs 
scrambled (B) Quantitative real-time RT-PCR show a significant decrease in expression 
levels of p47phox and p22phox in carotid tissue from ApoE−/− mice treated with Nox2ds 
peptide compared with ApoE−/− mice treated with scrambled (*P = 0.02, **P = 0.01 vs 
scrambled). A slight but not significant decrease in Nox1 expression is also observed in 
ApoE−/−mice treated with Nox2ds peptide.
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Fig. 2. 
Effect of Nox2ds-tat peptide on superoxide production: Immunofluorescence images of 
DHE-stained fresh-frozen sections of ApoE−/− arteries. Animals were treated with Control 
diet or HFD plus peptides. Results are typical of staining of sections from four different 
aortas in each group. Digital scans of intimal regions of DHE stained aortas were quantified 
using ImageJ (NIH) software. Results shown are mean ± SEM. *P < 0.05 vs control; §P < 
0.05 vs HFD + scrambled.
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Fig. 3. 
Effect of Nox2ds-tat peptide on atherosclerotic lesion in ApoE−/− mice Fed with High-fat 
Diet. Atheroma development in the whole aorta (aortic arch up to abdominal aorta) was 
quantified by computerized morphometry. ApoE−/− mice were fed control diet or HFD 
during 8 weeks and treated with Nox2ds peptide or scrambled during last 2 weeks. Arteries 
were stained with Oil-red O and results represent the area of lesion (μm2 × 103) relative to 
total aortic surface (n = 6 mice per group). P < 0.001 vs HFD+ Nox2ds peptide.
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Fig. 4. 
Effect of Nox2ds-tat peptide on protein expression and gelatinolytic activity of MMP-9. (A) 
Expression of MMP-9 determined by Western Blot in carotid arteries homogenates from 
ApoE−/ − ice (n = 4 each group) fed with control diet, HFD during 8 weeks and treated with 
Nox2ds peptide or scrambled during last 2 weeks. β-actin protein was used as control for 
relevant quantification. Results are means ± S.E.M, from two independent experiments 
(Density plot for n = 2 experiments) *P < 0.05 vs control diet. (B) MMP-9 activity was 
measured by gelatin zymography in carotid arteries homogenates from the same groups 
mentioned above. The enzyme gelatinolytic activity was determined by densitometry and 
analyzed with ImageJ Software. Collagenase was used as a positive control. Results, 
expressed as % relative control, are means ± S.E.M, from two independent experiments. *P 
< 0.05 vs control diet §P < 0.01 vs HFD + Scr.
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Table 2
Fold differences in gene expression of pro-angiogenic markers.
Markers Fold increase
Control chow HFD + Scrambled HFD + Nox2ds-tat
VEGF 1.0 ± 0.20 11.1 ± 0.1*** 7.8 ± 0.2***,#
HIF-1a 1.0 ± 0.04 2.74 ± 0.15** 1.6 ± 0.1*,#
VISFATIN 1.0 ± 0.01 3.66 ± 0.52** 0.66 ± 0.02#
MMP-9 1.0 ± 0.03 1.69 ± 0.14** 0.64 ± 0.04#
mRNA expression was analyzed in carotic artery wall from ApoE-KO mice (n = 4) treated with control diet, or high fat diet (HFD) plus peptides, 
Scrambled or Nox2ds-tat. Gene expression level of the measured genes in control diet was set at 1. The corresponding ΔCt values are means ± 
SEM.
*
P< 0.01;
**
P < 0.001;
***
P < 0.0001 vs control diet;
#
P < 0.01 vs HFD + Scrambled.
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